Analysts expect Stemline Therapeutics Inc (NASDAQ:STML) to report earnings of ($0.47) per share for the current fiscal quarter, according to Zacks. Five analysts have provided estimates for Stemline Therapeutics’ earnings, with estimates ranging from ($0.54) to ($0.38). Stemline Therapeutics posted earnings per share of ($0.66) during the same quarter last year, which indicates a positive year over year growth rate of 28.8%. The company is expected to announce its next earnings report on Thursday, August 8th.
On average, analysts expect that Stemline Therapeutics will report full year earnings of ($2.09) per share for the current year, with EPS estimates ranging from ($3.01) to ($1.55). For the next financial year, analysts expect that the firm will report earnings of $0.29 per share, with EPS estimates ranging from ($1.25) to $2.12. Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research firms that cover Stemline Therapeutics.
Stemline Therapeutics (NASDAQ:STML) last issued its earnings results on Friday, May 10th. The biopharmaceutical company reported ($0.73) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.67) by ($0.06). The firm had revenue of $5.05 million during the quarter, compared to analyst estimates of $2.61 million.
Several research analysts have recently weighed in on STML shares. Wedbush restated a “buy” rating and set a $95.00 target price on shares of Global Blood Therapeutics in a report on Monday, May 13th. ValuEngine upgraded Vermillion from a “hold” rating to a “buy” rating in a report on Wednesday, May 15th. Roth Capital restated a “buy” rating on shares of Resverlogix in a report on Thursday, May 23rd. BidaskClub raised shares of Zynerba Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, July 4th. Finally, HC Wainwright set a $35.00 price target on shares of Stemline Therapeutics and gave the company a “buy” rating in a research report on Thursday, June 20th. Four investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $25.20.
In other Stemline Therapeutics news, COO Kenneth Hoberman sold 25,817 shares of the business’s stock in a transaction that occurred on Tuesday, May 14th. The stock was sold at an average price of $14.27, for a total value of $368,408.59. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Ivan Bergstein sold 56,316 shares of the business’s stock in a transaction that occurred on Wednesday, June 26th. The shares were sold at an average price of $15.08, for a total value of $849,245.28. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 149,177 shares of company stock worth $2,236,377. Corporate insiders own 13.10% of the company’s stock.
Large investors have recently bought and sold shares of the business. Rhumbline Advisers raised its holdings in shares of Stemline Therapeutics by 47.2% during the fourth quarter. Rhumbline Advisers now owns 37,138 shares of the biopharmaceutical company’s stock valued at $353,000 after acquiring an additional 11,911 shares during the period. BlackRock Inc. grew its position in Stemline Therapeutics by 4.9% in the fourth quarter. BlackRock Inc. now owns 2,065,239 shares of the biopharmaceutical company’s stock worth $19,618,000 after acquiring an additional 95,747 shares in the last quarter. Bank of New York Mellon Corp grew its position in Stemline Therapeutics by 26.5% in the fourth quarter. Bank of New York Mellon Corp now owns 134,756 shares of the biopharmaceutical company’s stock worth $1,281,000 after acquiring an additional 28,198 shares in the last quarter. Great West Life Assurance Co. Can acquired a new stake in shares of Stemline Therapeutics in the fourth quarter worth $47,000. Finally, Dimensional Fund Advisors LP lifted its stake in shares of Stemline Therapeutics by 8.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 185,395 shares of the biopharmaceutical company’s stock worth $1,761,000 after buying an additional 14,275 shares during the last quarter. Institutional investors and hedge funds own 77.66% of the company’s stock.
Shares of Stemline Therapeutics stock traded up $0.32 on Friday, hitting $13.34. 5,220 shares of the company were exchanged, compared to its average volume of 392,389. The stock has a market cap of $586.25 million, a PE ratio of -4.41 and a beta of 1.33. The stock’s 50-day moving average is $14.27. Stemline Therapeutics has a 1-year low of $7.82 and a 1-year high of $17.85. The company has a quick ratio of 5.03, a current ratio of 5.07 and a debt-to-equity ratio of 0.01.
Stemline Therapeutics Company Profile
Stemline Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of oncology therapeutics in the United States and internationally. The company offers ELZONRIS, a targeted therapy directed to the interleukin-3 receptor (CD123) for patients with blastic plasmacytoid dendritic cell neoplasm in adults, and in pediatric patients two years and older.
Featured Story: Stock Symbols and CUSIP Explained
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.